Targacept in colitis agreement

Published: 30-Apr-2001


Targacept of Winston-Salem, NC, US, has entered into a joint research, development and commercialisation agreement with Dr Falk Pharma of Freiburg, Germany to develop a new class of drugs to treat ulcerative colitis. The two companies will jointly develop Targacept compounds into products for the European market. Dr Falk will have distribution rights in Europe, Israel and Egypt, and Targacept for the rest of the world.

You may also like